T he population is aging rapidly worldwide, which will lead to an increased societal and economic burden of age-associated chronic disease, including cardiovascular diseases. 1, 2 Cardiovascular diseases remain the leading cause of morbidity and mortality in developed nations, and chronological age is the primary risk factor for cardiovascular diseases. 3 Arterial stiffness and blood pressure (BP) both increase with advancing age [4] [5] [6] [7] and are independent predictors of cardiovascular (CV) events and mortality. 8, 9 As such, there is strong, ongoing demand for evidence-based strategies that prevent, delay, or reverse age-associated increases in BP and arterial stiffness. 10, 11 Indeed, the need for new approaches is expected to grow as the burden of age-and accelerated aging-associated cardiovascular dysfunction and disease continues to rise. In this review, we discuss the concept of healthy vascular aging (HVA) with regard to definition and contributing mechanisms, existing and promising HVA-enhancing lifestyle-and pharmacological-based strategies, and future directions. The focus will be primarily on data from observational and intervention studies in humans.
Components of HVA and Related Implications
Arterial stiffening and increases in BP occur with advancing age [4] [5] [6] [7] although population-based studies indicate that this is not an inevitable consequence of aging but rather results from an industrialized lifestyle. 12, 13 The prevalence of hypertension dramatically increases with advancing age, affecting approximately two thirds of Americans ≥60 years. 3 Hypertension is also highly prevalent in populations with chronic disease, including chronic kidney disease (CKD) and type 2 diabetes mellitus. 14, 15 The most recent Joint National Commission 8 guidelines increased the BP treatment goal for individuals >60 years of age to <150/90 mm Hg with a goal of <140/90 mm Hg in adults 30 to 59 years of age, including individuals with diabetes mellitus and nondiabetic CKD. 16 However, the recently completed multicenter randomized controlled trial, SPRINT (Systolic Blood Pressure Intervention Trial), conducted nationwide in >9000 adults 17 challenged these guidelines. SPRINT was terminated early as a consequence of a 25% lower risk of the composite end point of CV events and death in individuals randomized to intensive BP lowering (systolic BP [SBP] <120 mm Hg) compared with standard treatment (SBP <140 mm Hg). Notably, this finding was persistent across subgroups, including CKD and older adults (≥75 years of age). 18 Although the technique used for BP measurement in SPRINT has been discussed, 19 the results of the trial have been influential because a new report from the American College of Cardiology and American Heart Association Task Force of Clinical Practice Guidelines now defines high BP as ≥130/80 mm Hg for all ages. 20 Large elastic artery stiffening (ie, aorta and carotid arteries) also occurs with advancing age and is greater at any age in patients with chronic disease, including CKD, 21 diabetes mellitus, 22 and hypertension. 23 As a result, these and other clinical disorders featuring such CV changes can be viewed as states of accelerated vascular aging. Multiple techniques exist to assess arterial stiffness, including local distensibility (eg, ultrasound and tonometry-measured carotid artery compliance), the carotid or aortic augmentation index, aortic distensibility by magnetic resonance imaging, and pulse-wave velocity (PWV; assessed between 2 arterial segments), as reviewed elsewhere. [24] [25] [26] Of note, augmentation index is generally not considered an accurate marker of arterial stiffness because it is strongly influenced by heart rate, height, and contractility and decreases in older age. 24, 25 As a result, augmentation index has not been included in the present assessment of the literature. Carotid-femoral PWV (CFPWV) is considered the gold-standard technique, measuring stiffness of the aorta, 27 and can be measured by applanation tonometry or Doppler flow recordings. Unlike arterial BP, no formal medical guidelines or targets exist for CFPWV nor is CFPWV routinely measured clinically; however, both 12 and 10 m/s have been suggested as cutoffs for increased risk of CV events. 27, 28 Arterial stiffness and BP/hypertension are dynamically interconnected, with each factor influencing the other in a bidirectional manner. Although arterial stiffness was long considered to be a complication of hypertension, there is growing evidence that arterial stiffening can precede the increase in SBP and that an elevation of SBP further augments arterial stiffness. [29] [30] [31] Arterial stiffness increases in the aorta and carotid arteries with aging, with a lack of stiffening in the large peripheral muscular arteries, thus reducing peripheral impedance to the forward component of the arterial pulse-wave and increasing pulsatile energy transmission to the microcirculation. 32 This increased blood flow and pressure pulsatility can lead to damage of high flow, low impedance organs, including the kidneys and brain. 32 Indeed, increases in arterial stiffness are associated with declines in renal function 21, 33 and are considered a hallmark of end-stage renal disease. 34 CFPWV is also independently associated with cognitive decline, 35, 36 consistent with the concept of increased pulsatile energy transmission damaging the brain microcirculation and parenchymal tissues.
In addition, aortic stiffening-associated increases in pressure pulsatility and systolic load promote left ventricular remodeling featuring hypertrophy and dysfunction. 37, 38 Recently in this journal, Niiranen et al 39 demonstrated in a community-dwelling cohort of middle-aged and older (MA/O) adults from the Framingham Heart Study that HVA was independently associated with lower risk of incident CV events. HVA was defined as CFPWV <7.6 m/s (mean±2 SD of a reference group of individuals <30 years of age) in combination with absence of hypertension (using the previous guideline SBP/diastolic BP cutoff of 140/90 mm Hg; Figure 1 ). These findings are consistent with evidence that increased CFPWV is an independent predictor of incident CV events and mortality 8, 9 and improves prediction over traditional risk factors alone, including BP. 8, 40 Building on the concept of HVA, this review will discuss mechanisms influencing HVA, as well as preventive strategies and therapeutic approaches for preserving/attaining HVA. Of note, few interventions have achieved HVA in individuals or groups that lack HVA status at baseline when applying the definition used in the Framingham Heart Study. 39 As such, we will include studies that achieved significant CFPWV lowering, with or without changes in BP, even if full restoration of HVA status was not attained. Last, although the Framingham Heart Study definition of HVA used SBP and diastolic BP to define BP component of this index, it should be emphasized that mean arterial pressure exerts an important physiological influence on arterial stiffness 41 and must be considered when assessing changes in CFPWV in response to the preventive and treatment strategies discussed below.
Mechanisms Influencing HVA

Modulation of BP With Aging
As the large elastic arteries become stiffer with aging, SBP increases, whereas diastolic BP decreases because of lessening of elastic recoil of the aorta 29, 42 ; as a result, pulse pressure widens with advancing age. 43 Isolated systolic hypertension is the most common form of hypertension in individuals ≥50 years. 44 Increases in large elastic artery stiffness are a major contributor to these changes in BP with aging, ultimately promoting the development of systolic hypertension. [29] [30] [31] Age-associated endothelial dysfunction featuring decreased nitric oxide (NO) bioavailability and increased endothelin-1 production, as well as dysregulated vascular tone, further contribute to increased SBP ( Figure 2) . 45, 46 These events are mediated, in part, by increased oxidative stress associated with excessive superoxide production. 47 An interaction between the immune system and hypertension also may be involved because immune activation and inflammation promoted by oxidative stress are implicated in the development of hypertension. 48 In addition, with advancing age, sympathetic nervous system activity increases, and the association between sympathetic nervous system activity and BP becomes stronger, particularly in women. 49 Furthermore, chronic activation of the renin-angiotensin system promotes target organ damage, including the kidney and heart, because angiotensin II induces both increased BP and reactive oxygen species production.
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Modulation of Arterial Stiffness With Aging
Both functional and structural influences modulate arterial stiffness with aging. Functionally, arterial stiffness is modulated, in part, by the vasoconstrictor tone produced by the contractile state of vascular smooth muscle cells. 42 Ageassociated vascular endothelial dysfunction interacts closely with arterial stiffness 51 as endothelial NO synthase uncoupling can promote vascular remodeling and increased arterial stiffness via decreased NO bioavailability, 52, 53 which may be exacerbated by oxidative stress. 54, 55 Age-associated neurohumoral dysfunction, resulting from decreased sympathetic baroreflex sensitivity and increased sympathetic activation, also promotes arterial stiffness, and vice-versa. 56 Systemic inflammation, which also increases with aging, may contribute to arterial stiffness via immune activation and the development of hypertension. 57 Structurally, extracellular matrix remodeling alters the composition of elastin and collagen in the large elastic arteries with advancing age. The medial layer undergoes elastin fragmentation and degradation, 43, 58 which is mediated, in part, by upregulation of matrix metalloproteinases. 59 Collagen deposition occurs, replacing the loss of elastin molecules, 43, 58 and accelerated formation of advanced glycation end products promotes cross-linking of structural proteins and exacerbates increases in arterial stiffness. 60 Oxidative stress and inflammation drive these structural changes via vascular damage, smooth muscle cell proliferation, and arterial remodeling. 61, 62 Angiotensin II may also modulate structural contributions to arterial stiffness by stimulating collagen formation, reducing elastin synthesis, and promoting matrix remodeling in addition to influencing NO signaling and reactive oxygen species production. 63 Not only do changes in the extracellular matrix contribute to arterial stiffness, but intrinsic stiffening of the vascular smooth muscle cells, as measured by atomic force microscopy, also occurs with aging as well as hypertension. 64, 65 Of note, intimal-medial thickening occurs with aging even in the absence of atherosclerotic plaques, mediated primarily by thickening of the intima, 10 and is positively correlated with CFPWV in older adults. 66, 67 Age-associated disease processes, including diabetes mellitus (via impaired glucose tolerance) 68 and CKD (via vascular calcification), 69 can further exacerbate arterial stiffness.
It is difficult to separate hypertension and arterial stiffness because of their bidirectional interaction, common mechanisms, and overlapping presence in aging and age-associated disease. Although hypertension can promote aortic stiffening, large elastic artery stiffening may precede and promote an increase in SBP. 29, 38 Large elastic artery stiffness is an independent predictor of incident hypertension in multiple longitudinal cohorts. 30, 70, 71 In addition, in rodents fed a high-fat, high-sucrose diet, increased aortic PWV is evident before an elevation in SBP. 31 Notably, there are some interventions that have reduced arterial stiffness in a manner deemed at least partially BP independent. [72] [73] [74] [75] Although, in general, interventions with the most profound influence on CFPWV typically also demonstrate a large SBP-lowering effect, there are examples in which arterial stiffness is reduced without lowering SBP. Of note, most of these latter examples have tended to be in populations without hypertension. Arterial stiffness and BP may be even more tightly intertwined when BP is already elevated.
Lifestyle-Based Strategies to Maintain or
Restore HVA
In this section, we will focus on lifestyle-based strategies (aerobic exercise, caloric restriction-based weight loss, and changes in diet composition) with evidence from randomized controlled trials demonstrating a reduction in CFPWV with or without changes in SBP. Using an approach used previously, 76 in Figure 3 we summarize current knowledge on the lifestylebased strategies described below, including a semiquantitative assessment of the weight of the available evidence for efficacy based on our review of the relevant literature.
Aerobic Exercise
The original observation associating aerobic exercise with HVA is from 1993 in rigorously screened healthy adults (primarily men) who participated in the Baltimore Longitudinal Study of Aging. 77 In this cohort, CFPWV was lower in masters (MA/O) endurance trained athletes compared to sedentary peers, suggesting that aerobic exercise may attenuate the age-associated increase in arterial stiffness. Subsequently, a similar observation was made in postmenopausal women with normal BP. 78 Consistent with these cross-sectional findings, intervention studies conducted in healthy MA/O adults have demonstrated a significant reduction in arterial stiffness with aerobic exercise training. This was first demonstrated as an improvement in carotid artery compliance after a 3-month walking program administered to men, 79 and later to postmenopausal women, 80 consistent with earlier evidence of reduced arterial stiffness with 4 weeks of exercise training in healthy young sedentary men. 81 Although a moderate intensity aerobic exercise intervention of similar duration was later shown to reduce CFPWV in healthy MA/O men 82 and women, 83 the reductions in CFPWV were small and not clearly independent of small decreases in BP. Moreover, no improvement in CFPWV with exercise was observed in a year-long study conducted in healthy older adults, 84 and similar findings were reported in a group of overweight MA/O adults. 85 In general, these trials on aerobic exercise and arterial stiffness in normotensive healthy adults reported little or no change in SBP.
The available evidence indicates a lack of efficacy of moderate intensity aerobic exercise for reducing CFPWV in MA/O adults with hypertension 86, 87 although exercise has been reported to reduce CFPWV in young to middle-aged prehypertensive and hypertensive adults. 88 A recent meta-analysis of 14 aerobic exercise trials conducted in prehypertensive and hypertensive adults concluded that aerobic exercise does not reduce arterial stiffness although various indices of arterial stiffness were combined in this analysis. 89 The efficacy of an aerobic exercise intervention to reduce arterial stiffness in the setting of age-associated disease is mixed. Although reductions in CFPWV and SBP have been observed with exercise training in adults with metabolic syndrome, 90 aerobic exercise has been reported to both lower and have no effect on CFPWV and SBP in MA/O adults with type 2 diabetes mellitus. 91, 92 Similarly, aerobic exercise does not seem to reduce CFPWV or SBP in patients with moderate to severe CKD 93, 94 although intradialytic exercise (ie, during a dialysis session) may be efficacious in chronic dialysis patients. 95 Overall, aerobic exercise seems to be an evidence-based public health strategy for maintaining or restoring HVA in the setting of healthy (nonhypertensive) aging and in some diseases associated with accelerated vascular aging although there are some inconsistencies across studies. The improvements in CFPWV seem at times to be independent of any change in BP, particularly in healthy MA/O adults who are free from hypertension. Of note, in contrast to aerobic exercise, resistance exercise training does not seem to reduce arterial stiffness, 96 and intensive resistance exercise training performed without complementary aerobic exercise activities may actually increase CFPWV in young healthy individuals, 97 consistent with earlier cross-sectional observations. 98 Of note to public health translation, however, are data indicating limited adherence to aerobic exercise in long-term trials 99 and in accordance with federal activity guidelines.
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Weight Loss and Total Energy Intake
Short-term (ie, ≤3 months) caloric restriction-based weight loss administered in MA/O healthy overweight and obese adults significantly reduces CFPWV. [101] [102] [103] Similar improvements are observed with 1 year of caloric restriction-based weight loss. 104 The SBP-lowering effect in these trials was also notable (between 6 and 15 mm Hg in individuals free from hypertension at baseline). Caloric restriction-based weight loss is also efficacious for reducing CFPWV when administered in conjunction with other lifestyle interventions. Weight loss from an energy-restricted diet plus exercise reduces CFPWV and slightly decreases SBP in young overweight and obese adults. 105 In overweight and obese adults with moderately elevated SBP, caloric restriction-based weight loss in conjunction with the DASH (Dietary Approaches to Stop Hypertension) diet reduces both CFPWV and SBP. 106 Of note, these improvements may have been mediated, at least in part, by the 30% reduction in sodium intake associated with the diet rather than by weight loss alone. The combination of reduction in total energy intake, exercise, and sodium restriction also has a significant CFPWVand SBP-lowering effect in young to middle-aged, normotensive, overweight and obese adults. 105, 107 Similarly, in adults with type 2 diabetes mellitus, the combination of weight loss via energy restriction, exercise, and the weight loss medication Orlistat promotes a profound lowering of CFPWV. 108 In contrast to a shorter-term caloric restriction-based weight loss intervention, lifelong caloric restriction is challenging in humans because of adherence and has risk of negative side effects (such as loss of bone density and lean muscle mass observed in the recent 2-year CALERIE [Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy] trial of 25% caloric restriction in nonobese, healthy, younger adults). 109 Nevertheless, lifelong caloric restriction in mice (40% reduction) prevents age-related increases in both aortic PWV and SBP. 110 In addition, in a case-control study in MA/O humans, those self-practicing caloric restriction (n=18) for an average of 6 years had substantially lower SBP than age-matched healthy controls consuming a typical American diet, 111 and preliminary 
Dietary Components and Dietary Patterns
Dietary Sodium Restriction
The first observation linking dietary sodium intake to arterial stiffness is a case-control study from 1986, which compared CFPWV in normotensive adults who voluntarily followed a low-sodium diet (mean intake 44 mmol/d) for an average of 2 years to controls with the same mean arterial pressure. CFPWV was substantially lower in MA/O adults who practiced dietary sodium restriction. 114 Subsequently, 5 trials of dietary sodium restriction have been conducted with CFPWV as an end point in MA/O, healthy adults of varying SBP (normotensive to hypertensive). 87, [115] [116] [117] [118] CFPWV was significantly reduced in 4 of these trials, 87, [116] [117] [118] and SBP was lowered in all 5. Of note, in 2 of these trials, individuals lacking HVA by the Framingham definition at baseline were restored to HVA status by dietary sodium restriction (Figure 4) . 87, 118 The efficacy of this intervention for restoring HVA is further supported by evidence that dietary sodium restriction rapidly improves carotid artery compliance, another index of arterial stiffness, in MA/O adults with moderately elevated SBP. 119 Trials of dietary sodium restriction in populations of accelerated aging diseases are lacking. One crossover trial of dietary sodium restriction has been conducted in hypertensive patients with stages 3 to 4 CKD, which demonstrated a nonsignificant reduction of CFPWV with a strong SBP-lowering effect. 120 It also merits mention that sodium intake interacts closely with dietary potassium intake to influence CV risk. 121 Evidence on the effect of potassium supplementation on CFPWV in healthy adults is mixed, 72, 122 and the interactions of dietary sodium and potassium intake on CFPWV warrant additional research. Overall, dietary sodium restriction has a consistent SBP-lowering effect and significantly reduces CFPWV in healthy MA/O adults. Thus, dietary sodium restriction represents an important public health strategy to maintain or restore HVA although further research is needed in populations with clinical disorders. Despite challenges in adhering to a low-sodium diet, policy changes implemented at a national level in Finland support that population-level reductions in dietary sodium intake are possible. 123 
Flavonoids
Flavonoids are low molecular weight compounds composed of a 3-ring structure with various substitutions and are found in abundance in citrus fruits, seeds, olive oil, tea, and red wine. 124 Isoflavones are 1 class of flavonoids, found most often in legumes, including soybeans. 125 Administration of isoflavones or an isoflavone metabolite reduces CFPWV in healthy MA/O men and postmenopausal women with or without altering SBP. 74, 126 Flavanones, flavanols, and anthocyanins are other classes of flavonoids 124 with evidence of reducing CFPWV. 73, [127] [128] [129] Grapefruit juice with high flavanones reduces CFPWV without lowering SBP in postmenopausal women with a large abdominal circumference. 73 Similarly, cocoa flavanols reduce CFPWV in healthy MA/O men, 127 as well as young healthy adults, 128 and postmenopausal women with type 2 diabetes mellitus, 129 along with possible reductions in SBP. 127, 128 Finally, cranberry juice with anthocyanins and polyphenols reduces CFPWV without changing SBP in MA/O adults with coronary artery disease. 75 Thus, there is evidence that flavonoids may reduce CFPWV with or without changes in SBP. Notably, adverse reactions are rare. and flavonoids seem to have an exceptional safety record. 124 
Dietary Patterns
Specific patterns of dietary intake may modulate HVA. In a longitudinal cohort followed for 27 years, vegetable intake in childhood and persistently high consumption of fruits and and carotid-femoral pulse-wave velocity (CFPWV; bottom) in postmenopausal women (black bars) and postmenopausal women and middle-aged and older men (white bars) with elevated blood pressure in response to a low-sodium diet compared with normal sodium intake (30-50% restriction). Individuals lacking HVA by the Framingham definition at baseline were restored to HVA status by dietary sodium restriction in both studies, as indicated by the reductions in SBP and CFPWV from the red-to the green-shaded zone (above and below the dashed line). Data derived from Seals et al 87 and Jablonski et al.
vegetable intake across the study period were independently associated with lower CFPWV in adulthood. 130 However, specific evidence on the effect of other dietary patterns, such as the Mediterranean or vegetarian diet on CFPWV, is currently lacking although alternate measurements of arterial stiffness suggest that such patterns may lead to improvements. 76 In trials implementing dietary patterns, including DASH, the Mediterranean diet, and high fruit and vegetable intake, BP is also significantly reduced. 131 This topic clearly represents an important and presently understudied area of future research.
Pharmacological-Based Strategies to Maintain or Restore HVA
Numerous pharmacological agents, both those routinely prescribed as well as novel agents, represent potential strategies for maintaining or restoring HVA. Agents that will be discussed in the upcoming sections include antihypertensive medications, statins, mammalian target of rapamycin (mTOR) inhibitors, AMP-activated protein kinase (AMPK) activators, sirtuin activators, anti-proinflammatory cytokine therapies, peroxisome proliferator-activated receptor-γ activators, and antifibrotic drugs. In Figure 5 , we summarize current knowledge on the pharmacological strategies described below, including a semiquantitative assessment of the weight of the available evidence for efficacy based on our review of the relevant literature.
Antihypertensive Agents and BP Lowering
Trials evaluating the effect of antihypertensive agents on CFPWV have primarily been conducted in individuals with hypertension although additional evidence is provided from a few studies conducted in healthy volunteers. 132 Overall, most antihypertensive agents, including vasodilators, 133 β-blockers, 134, 135 calcium channel blockers, 136, 137 diuretics, 138 and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ARB), [138] [139] [140] [141] seem to have some effect on CFPWV, with the best long-term evidence existing for angiotensin-converting enzyme inhibitors/ARB agents. Of note, β-blockers may be less useful because the slowing of heart rate (HR) can increase pulse pressure and central pressure augmentation. 142 Spironolactone also significantly lowers CFPWV in patients with stages 2 to 3 CKD already on angiotensin-converting enzyme inhibitors/ARBs with good BP control. 143 It may be the degree of SBP lowering induced that is more important than the medication class on the effect on CFPWV. In SPRINT, 17 CFPWV was measured in a subgroup of participants in an ancillary study, including a large number of patients with CKD and adults ≥75 years of age. The data are pending but will provide important evidence on the influence of long-term BP control (regardless of medication class) on arterial stiffness. A small study conducted in nondiabetic, hypertensive older adults suggests that intensive BP control does more effectively reduce CFPWV than standard BP management. 144 However, despite well-known benefits of antihypertensive therapies, adherence is often suboptimal, particularly among older adults with multiple comorbid conditions, and both drug-drug and drug-disease interactions increase the risk of adverse events with advancing age.
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Statins
Numerous trials have assessed the effect of statins (HMG-CoA [3-hydroxy-3-methylglutaryl-coenzyme] reductase inhibitors) in CFPWV in MA/O adults with hypercholesterolemia, isolated systolic hypertension, or who are overweight/obese. [146] [147] [148] [149] [150] [151] [152] With the exception of 1 trial, 151 these studies have consistently reported significant reductions in CFPWV, generally without changing SBP. 146, [148] [149] [150] The combination of a statin and an ARB also lowers CFPWV in healthy middle-aged men. 153 Overall, statins seem effective at lowering CFPWV without changing SBP in MA/O adults. Statins have a well-established Figure 5 . Summary of pharmacologicalbased strategies to maintain or restore healthy vascular aging. Note: under Effects, ↓ represents a reduction, ↔ represents weak or conflicting evidence, and (?) represents a lack of available data for the indicated outcome (for arterial stiffness, this refers specifically to data on carotid-femoral pulse-wave velocity). Under Evidence, human and mouse symbols represent clinical and preclinical evidence, respectively, and the number of symbols reflects the approximate semiquantitative weight of evidence available for each strategy based on the authors' review of the literature. For details, see references/ discussion in the text. AMPK indicates AMP-activated protein kinase; HDL, highdensity lipoprotein; IL-1β, interleukin-1 β; LDL, low-density lipoprotein; mTOR, mammalian target of rapamycin; PPAR-γ, peroxisome proliferator-activated receptor γ; SAC, sirtuin activating compound; and TNFα, tumor necrosis factor-α. safety profile, although similar to antihypertensive agents, adherence can be suboptimal, particularly with advancing age. 145 Because both antihypertensive agents and statins are commonly prescribed medications with advancing age, they should be considered effective strategies to maintain or restore HVA. This conclusion also emphasizes the importance of considering these effects when studying the efficacy of other interventions in populations taking these agents at baseline.
mTOR Inhibitors, AMPK Activators, and Sirtuin Activators
With advancing age, nutrient sensing pathways, including mTOR, AMPK, and sirtuins, become dysregulated. 154 These pathways are among those modulated by chronic caloric restriction and, therefore, pharmacological manipulation might produce similar CV effects. 76, 155 As such, interventions targeting these pathways may help maintain or restore HVA.
In a clinical trial that converted kidney transplant recipients from immunosuppression with cyclosporine A to the mTOR inhibitor sirolimus (both in addition to mycophenolate mofetil), conversion significantly reduced CFPWV, suggesting that mTOR inhibition reduces arterial stiffness. 156 BP was also reduced but may have been mediated by improved renal function and medication adjustments. The reduction in arterial stiffness is consistent with evidence that mTOR inhibition with rapamycin reduces aortic PWV in old mice (although without obviously changing BP). 157 However, rapamycin has notable side effects, including the potential for metabolic dysregulation, which may limit its CV health-promoting effects. 158 Consequently, safer analogs of rapamycin (rapalogs) are being developed as alternate therapies. 159 The AMPK activator metformin is another potential novel therapy to maintain or restore HVA. As proof of concept, metformin reduces CFPWV and BP in young women with polycystic ovary syndrome and is also well tolerated, 160 thus may also reduce arterial stiffness in other states of impaired AMPK activation, including aging. Finally, sirtuin activators, including resveratrol and NAD + precursors, such as nicotinamide mononucleotide and nicotinamide riboside, are other potential strategies to reduce age-associated arterial stiffness. Resveratrol is a polyphenol found in red wine, grapes, and other berries and activates sirtuin-1. 155 In nonhuman primates, resveratrol ameliorates high-fat and high-sucrose diet-induced increases in aortic PWV without changing BP. 161 Resveratrol also inhibits the mTOR/S6 kinase pathway. 162 Of note, resveratrol may have off-target effects when administered in combination with other healthy lifestyle practices. 155 Another potential strategy to augment the age-associated decline in sirtuin-1 activity is to increase bioavailability of the cosubstrate NAD + . 163 For example, supplementation with nicotinamide mononucleotide reduces aortic PWV without obviously changing BP in old mice, 164 and supplementation with nicotinamide riboside reduces BP and CFPWV in MA/O adults, particularly those with prehypertensive levels of SBP. 165 However, additional research about the efficacy of NAD + boosting and other sirtuin-activating compounds for reducing arterial stiffness in humans is needed, including data on clinical disorders of accelerating CV aging.
Anti-Proinflammatory Cytokine Therapies
Anti-proinflammatory cytokine therapies are a potential novel therapeutic to restore HVA. Tumor necrosis factor-α antagonism reduces CFPWV without changing BP in chronic inflammatory diseases associated with increased aortic stiffness, such as rheumatoid arthritis, [166] [167] [168] but the potential side effects of anti-proinflammatory cytokine therapies may limit use in healthy aging populations. Of note, in the recently completed CANTOS (Canakimumab Anti-Inflammatory Thrombosis Outcomes Study), which enrolled >10 000 patients with stable coronary artery disease and elevated C-reactive protein levels, the interleukin-1β inhibitor canakinumab significantly reduced risk of major CV events by 15%. 169 These results provide initial support for the efficacy of anti-proinflammatory therapies for treating (and potentially preventing) CV diseases and restoring HVA. However, the higher incidence of fatal infection observed with canakinumab may limit translation to a healthy again population.
Peroxisome Proliferator-Activated Receptor-γ Activation
Peroxisome proliferator-activated receptor-γ is a regulator of fatty acid storage and glucose metabolism and is activated by the thiazolidinedione pioglitazone. Short-term treatment with pioglitazone reduces brachial-ankle PWV in patients with type 2 diabetes mellitus 170 and carotid-radial PWV in obese men with impaired glucose tolerance, 171 without changing BP. However, the effects of these compounds on CFPWV and in the settings of age-and disease-associated arterial stiffening are currently unknown, and potential side effects of weight gain, edema, shortness of breath, and bone fracture need to be considered.
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Antifibrotic Agents
Pirfenidone is an antifibrotic agent that inhibits transforming growth factor-β, tumor necrosis factor-α, and other growth factors and interferes with matrix formation. 173 It is prescribed clinically to treat idiopathic pulmonary fibrosis and is generally safe with an acceptable side effect profile. 174 In a rodent model of diabetes mellitus, pirfenidone reverses cardiac fibrosis, attenuates cardiac stiffness, and also reduces renal fibrosis (without changing BP) and thus may hold promise in attenuating age-associated aortic stiffening. 175 Overall, it is likely that novel pharmacological agents will have a future role in the treatment of diseases of accelerated vascular aging. Their use in the setting of healthy aging, to maintain or restore HVA, will require a more discerning consideration weighing potential side effects against potential benefits.
Mechanisms of Action
As discussed previously, arterial stiffness and elevated BP share common mechanisms and bidirectional interactions (Figure 2 ). In general, shorter duration interventions are more likely to modulate functional components of arterial stiffness (vascular smooth muscle tone) and to lower BP than to change arterial structure (eg, collagen or elastin composition) because the latter changes may require a long-term treatment period (eg, years) to induce. 79, 110 Structural changes may be even more difficult to reverse in disease states, such as CKD, which is additionally characterized by medial calcification.
Lifestyle-Based Strategies
We will focus this section on mechanisms by which lifestylebased strategies may modulate arterial stiffness rather than BP, and the reader is referred elsewhere for a discussion of the latter. 177, 178 Lifestyle-based strategies to maintain or restore HVA seem more likely to influence functional components of arterial stiffness although it is challenging to discern any structural changes that may occur if such interventions were maintained for a longer duration than typically evaluated in a randomized controlled trial.
Aerobic exercise likely influences functional components of arterial stiffness, such as increased NO production, 85 although long-term aerobic exercise may also influence arterial wall structure, including advanced glycation end products cross-linking of proteins. 179, 180 Indeed, results from preclinical work in mice support the possibility that aerobic exercise may induce structural changes in the large elastic arteries of older animals, including reductions in collagen I and III, transforming growth factor-β1, and reduced smooth muscle α-actin.
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Collectively, regression analyses in trials of caloric restriction-based weight loss suggest that reductions in arterial stiffness are independent of BP changes. Improvements in stiffness in these studies over a relatively short time period (eg, 12 weeks) suggest that regulation of smooth muscle tone likely plays a larger role than structural changes. Functional influences on arterial stiffness, including NO production, may be mediated in part by reductions in circulating insulin or changes in other hormones, such as leptin. 183 Reductions in arterial stiffness with caloric restriction-based weight loss may also be influenced by changes in diet composition, including dietary sodium restriction. Dietary sodium restriction rapidly improves carotid artery compliance, again suggesting a larger contribution of functional versus structural changes. 119 Indeed, dietary sodium restriction both reduces vascular oxidative stress and increases NO bioavailability in humans, 184 and rising sodium concentrations increase endothelial cell stiffness measured by atomic force microscopy, while downregulating NO production. 185 Reductions in the endogenous Na + /K + ATPase inhibitor marinobufagenin may also modulate the reductions in CFPWV with dietary sodium restriction. 118 At least with shorter-term administration, flavonoids seem to also modulate functional components of arterial stiffness. Isoflavones are vasodilatory, reducing endothelin-1, increasing NO bioavailability, and improving vascular endothelial function. 186 Flavanones may also increase NO bioavailability. 187 Finally, intake of fruits and vegetables may modulate arterial stiffness via the effects of individual bioactive nutrients and phytochemicals, as well as via reductions in oxidative stress, inflammation, and insulin resistance.
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Pharmacological-Based Strategies
Pharmacological-based strategies to maintain or restore HVA may modulate functional or structural components of arterial stiffness. Antihypertensive agents primarily target the functional (vasoconstrictive) component of arterial stiffness through a direct modulation of BP. 142 However angiotensin-converting enzyme inhibitors/ARBs may be particularly effective at reducing arterial stiffness and indeed are more efficacious in the long term than other antihypertensive agents because they also have antifibrotic effects. 190 Statins also modulate smooth muscle tone via increased NO bioavailability, 191 as well as reduced sympathetic neural activity 192 and oxidative stress. 193 Metformin promotes endothelial NO synthase activation by activating AMPK in the endothelium 194 and additionally inhibits nuclear factor κB signaling and decreases inflammation. 149 Metformin may also modify arterial stiffness and lower BP by promoting weight loss. 160 Additional agents modulating functional regulation of arterial stiffness are rapamycin, which activates arterial AMPK and decreases oxidative stress, 157 and resveratrol, which increases endothelial NO synthase activity, reduces superoxide generation by NAD(P)H oxidases, and reduces nuclear factor κB-mediated inflammation and oxidative stress. 161, 195, 196 Further research is needed regarding underlying mechanisms by which NAD + precursor may reduce BP and aortic stiffness, but sirtuin-1 activation may be involved. 164 Anti-proinflammatory cytokine therapies likely lower arterial stiffness via anti-inflammatory effects, 167, 168 and peroxisome proliferator-activated receptor-γ activation also reduces circulating markers of inflammation. 170, 171 Pharmacological agents may also target structural components of arterial stiffness, in particular antifibrotic agents. 142 Rapamycin also decreases collagen and advanced glycation end products in the aorta, suggesting reduced cross-linking of collagens by advanced glycation end products with treatment.
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Conclusions and Future Directions
In this review, we have discussed the concept of HVA and contributing mechanisms while also summarizing lifestyle-and pharmacological-based strategies to maintain or restore HVA in both healthy adults and patients with accelerated CV agingrelated clinical disorders. There are notable gaps in the currently available research literature on this topic and practical challenges to implementing these interventions ( Figure 6 ). In Figure 6 . Current gaps in knowledge and challenges related to establishing evidence-based strategies for healthy vascular aging. particular, there remains an unmet need to translate effective strategies to maintain or restore HVA in the clinic and at the public health level. An example of this is the ongoing effort to reduce sodium intake at a population level through policy statements, 197 including government-industry partnerships to reduce sodium intake in several countries, including Japan, Finland, and the United Kingdom. 198 At the same time, preclinical models should continue to be used to discern the mechanisms modulating HVA in both healthy aging and diseased populations (reverse translation). 199 Indeed, the combination of forward and reverse translational physiological approaches has been used effectively to better understand the mechanisms by which prevention and treatment strategies, such as dietary sodium restriction, modulate BP and vascular health. 199 Novel strategies to maintain or restore HVA continue to be developed and tested. Examples of promising lifestyle interventions include inspiratory muscle strength training (breathing against a resistive load), which lowers SBP in both normotensive adults and patients with sleep apnea, 200, 201 passive heat therapy, which lowers mean arterial BP and CFPWV even in young healthy adults, 202 and novel dietary interventions that may mimic the beneficial effects of long-term caloric restriction, including different forms of intermittent fasting. 155 New pharmacological agents also continue to be developed, including anti-proinflammatory cytokine therapeutics and antisenescence drugs. In addition, in individuals with type 2 diabetes mellitus and established cardiovascular disease, a selective sodium-glucose cotransporter inhibitor (empaglifozin) was recently shown to influence properties related to arterial stiffness while lowering SBP, thus may hold promise to maintain or restore HVA. 203 Notably, in the Framingham Heart study, only ≈1% of individuals >70 years of age met the criteria for HVA. 39 This observation highlights that it is difficult to maintain HVA into older age and that trials testing the efficacy of novel strategies are particularly needed for older adults. The recent SPRINT trial results indicate that this age group can indeed be responsive to an intervention, contrary to what may have been thought previously. 17 This was also the case for populations at high CV risk, including individuals with CKD. Thus, testing of novel interventions to restore HVA is also critically needed in diseases of accelerated CV aging, such as CKD and diabetes mellitus. An increased number of cardiovascular risk factors is also associated with a greater annual increase in CFPWV, thus likely contributing to the progressive reduction in the prevalence of HVA with advancing age. 204 Ultimately, shifting the distribution to a higher number of individuals with HVA status will reduce the burden of CV events and mortality in the population.
